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Abstract
Background: Two mature microRNAs (miRNAs), hsa-miR-125a-3p and hsa-miR-125a-5p (collectively referred to as hsa-
miR-125a-3p/5p), are derived from 3' and 5' ends of pre-miR-125a, respectively. Although impaired regulation of hsa-
miR-125a-5p has been observed in some tumors, the role of this miRNA in invasion and metastasis remains unclear, 
and few studies have examined the function of hsa-miR-125a-3p. In order to characterize the functions of hsa-miR-
125a-3p/5p in invasion and metastasis of non-small cell lung cancer (NSCLC), we investigated the relationships 
between hsa-miR-125a-3p/5p expression and lymph node metastasis in NSCLC tissues. We also explored the impact of 
expression of these miRNAs on invasive and migratory capabilities of lung cancer cells.
Methods: Expression of hsa-miR-125a-3p/5p in NSCLC tissues was explored using real-time PCR. The relationships 
between hsa-miR-125a-3p/5p expression and pathological stage or lymph node metastasis were assessed using the 
Spearman correlation test. For in vitro studies, lung cancer cells were transfected with sense and antisense 2'-O-methyl 
oligonucleotides for gain-of-function and loss-of-function experiments. Transwell experiments were performed to 
evaluate cellular migration and invasion.
Results: Expression of hsa-miR-125a-3p/5p was lower in NSCLC tissues than in adjacent normal lung tissues (LAC). 
Furthermore, the results from the Spearman correlation test showed a negative relationship between hsa-miR-125a-3p 
expression and pathological stage or lymph node metastasis and an inverse relationship between hsa-miR-125a-5p 
expression and pathological stage or lymph node metastasis. In vitro gain-of-function experiments indicated that hsa-
miR-125a-3p and hsa-miR-125a-5p function in an opposing manner, suppressing or enhancing cell migration and 
invasion in A549 and SPC-A-1 cell lines, respectively. These opposing functions were further validated by suppression 
of hsa-miR-125a-3p and hsa-miR-125a-5p expression in loss-of-function experiments.
Conclusion: Hsa-miR-125a-3p and hsa-miR-125a-5p play distinct roles in regulation of invasive and metastatic 
capabilities of lung cancer cells, consistent with the opposing correlations between the expression of these miRNAs 
and lymph node metastasis in NSCLC. These results provide new insights into the roles of miR-125a family members in 
the development of NSCLC.
Background
MicroRNAs (miRNAs) are a class of endogenous, non-
coding RNAs, approximately 20-24 nucleotides in length,
that are derived from longer transcripts termed pri-miR-
NAs and pre-miRNAs [1-5]. MiRNAs recognize target
mRNAs through partial complementarity to specific
sequences within the mRNAs and posttranscriptionally
regulate gene expression in multicellular organisms [6-9].
Emerging evidence has shown that human miRNA genes
are frequently located in cancer-associated genomic
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Page 2 of 13regions, and perturbed miRNA expression patterns have
been detected in many human cancers [10]. Therefore, it
is of utmost importance to further elucidate the biologi-
cal functions of miRNAs.
Recently, miRNAs have been shown to play a role in
invasion and metastasis [11-15]. For example, miR-155
may play an important role in the TGF-β-induced epithe-
lial-mesenchymal transition (EMT) and in cell migration
and invasion through targeting of the RhoA transcript
[16]. MiR-21 has been shown to stimulate cell invasion
and metastasis in several tumor models, including breast
cancer [12], colon cancer [17], and glioma [18]. MiR-10b
can be activated by the pro-metastatic transcription fac-
tor TWIST1 and is essential for TWIST1-induced EMT
involved in promotion of cell motility and invasiveness
[19]. Tumor invasion and metastasis are the critical steps
that define the prognosis of cancer patients. Therefore,
understanding the specific roles of miRNAs in cancer
progression could lead to the identification of predictive
markers and the development of novel therapeutic strate-
gies for patients with metastases.
MiR-125a is one of the many miRNAs that remain to be
fully characterized. Using miRNA microarray analysis,
Yanainhara and colleagues [20] found that miR-125a, spe-
cifically the hsa-miR-125a-5p mature miRNA, is located
at 19q13.41 and that its expression is downregulated in
NSCLC. Recently, a new member of the mature miR-125a
family has been identified and named hsa-miR-125a-3p.
Unfortunately, the expression and function of hsa-miR-
125a-3p are currently unknown. In this study, we found
that expression of both hsa-miR-125a-5p and hsa-miR-
125a-3p is decreased significantly in NSCLC tissues in
comparison to LAC tissues. Changes in expression of
both hsa-miR-125a-3p and hsa-miR-125a-5p are associ-
ated with pathological stage and lymph node metastasis
in lung cancer, but in an opposing manner as shown by
the Spearman correlation test. In cellular studies, hsa-
miR-125a-3p and hsa-miR-125a-5p also appeared to
function in opposing manners in lung cancer cells, sup-
pressing or enhancing cell migration and invasion,
respectively. These results identify a potential role for the
miR-125a family in metastasis of NSCLC.
Methods
Samples
We analyzed 52 pairs of non-small cell lung cancer speci-
mens and corresponding normal lung tissues (LAC) col-
lected at the time of surgery and prior to chemotherapy.
Specimens were obtained from patients at the First Affili-
ated Hospital of China Medical University from 1 January
2006 to 1 December 2007 with informed consent. For the
majority of samples, clinical and biological information
was available. The study has been approved by the Hospi-
tals' Ethical Review Committee.
Cell culture
The HBE (Human Bronchiolar Epithelium) cell line and
the human lung cancer cell lines SPC-A-1 (adenocarci-
noma), LH7 and NCI-H460 (large cell cancinoma) were
propagated in RPMI1640 (Gibco). The A549 (adenocarci-
noma) cell line was propagated in Dulbecco's Modifed
Eagle Medium (Gibco). In both cases, the medium was
supplemented with 10% fetal bovine serum (FBS), 100 U/
ml penicillin, and 100 U/ml streptomycin. Cells were cul-
tured at 37°C in 5% CO2 until they reached a confluency
of 75%.
Transfection
Depletion of hsa-miR-125a-3p/5p in the A549 and SPC-
A-1 cell lines was achieved through transfection with
antisense 2'-O-methyl oligonucleotides directed against
hsa-miR-125a-3p/5p. Cells were transfected using Lipofe-
tamine™ 2000 (Invitrogen) according to the manufac-
turer's protocol.
Briefly, complexes containing the oligonucleotides were
prepared according to the recommended protocol and
added directly to cells at a final oligonucleotide concen-
tration of 0.4 nmol/mL. Oligonucleotides composed
entirely of 2'-O-methyl bases were chemically synthe-
sized by Integrated DNA Technologies (GeneChem) and
were comprised of the following sequences: 2'-O-Me-
sense-3p: 5'-ACA GGU GAG GUU CUU GGG AGCC-3'
2'-O-Me-antisense-3p: 5'-GGC UCC CAA GAA CC U
CAC CUGU-3', 2'-O-Me-scramble-3p: 5'-GGU CGG
UGC UCG AUG CAG GUAA-3', 2'-O-Me-sense-5p: 5'-
UCC CUG AGA CCC UUU AAC CUG UGA-3', 2'-O-
Me-antisense- 5p: 5'-UCA CAG GUU AAA GGG UCU
CAG GGA-3', 2'-O-Me-scramble-5p: 5'-GGA CG G CGA
UCA GAU AAG AGU UCU-3'. Cells were divided into
four groups: an untreated group incubated only in the
normal media (untreated), a group transfected with the
scrambled 2'-O-methyl oligonucleotide (scramble); a
group transfected with the sense 2'-O-methyl oligonucle-
otide (sense) and a group transfected with the antisense
2'-O-methyl oligonucleotide (antisense). The untreated
and scramble groups served as negative controls.
Quantitative real-time polymerase chain reaction (qRT-
PCR)
Expression of mature miRNAs was assayed using the
TaqMan MicroRNA Assay in accordance with the manu-
facturer's instructions (Applied Biosystems). All reac-
tions, including no-template controls and RT-minus
controls, were run in an ABI Prism 7900HT Sequence
detection system (Applied Biosystems). Specific RT prim-
ers and TaqMan probes were used to quantify the expres-
sion of hsa-miR-125a-3p (PN: 4395310) and hsa-miR-
125a-5p (PN: 4395309). Samples were normalized to
RNU6B (PN: 4373381) or U18 (PN: 4380904) as indi-
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ysis was performed in two independent experiments,
each using two independent samples. For quantification
of cell samples, RT-PCR analysis was performed in three
independent experiments, each using three independent
samples. MiRNA expression data is presented as fold dif-
ference relative to either RNU6B or U18 based on the fol-
lowing equation: RQ = 2-ΔΔCt.
Cell migration assays
For cell migration assays, 5 × 104 cells were trypsinized,
washed, resuspended in serum-free RPMI1640 or
DMEM, and placed in the top portion of the chamber.
The lower portion of the chamber contained 10% FBS for
use as a chemoattractant. The chambers were incubated
at 37°C in 5% CO2 for 24 h, washed with PBS, and fixed in
100% methanol. Following fixation, cells were stained
with Haematoxylin and imaged, and the number of
migrating cells was counted. Five random fields were ana-
lyzed for each chamber. Assays were conducted in dupli-
cate in three independent experiments.
Cell invasion assays
Pre-chilled serum-free RPMI1640 or DMEM was mixed
with Matrigel (1:7; BD Biosciences). The upper compart-
ments of the chambers were filled with 100 μ1 of the mix-
ture, and the Matrigel was allowed to solidify at room
temperature for 4 h. After solidification, 5 × 104 cells were
trypsinized, washed, resuspended in serum-free
RPMI1640 or DMEM, and placed in the top portion of
the chamber. The lower portion of the chamber con-
tained 10% FBS for use as a chemoattractant. The cham-
bers were incubated at 37°C in 5% CO2 for 24 h, washed
with PBS, and fixed in 100% methanol. Fixed cells were
stained with Haematoxylin and imaged, and the number
of invasive cells was counted. Five random fields were
analyzed for each chamber. Assays were conducted in
duplicate in three independent experiments.
Statistical analysis
The SPSS 13.0 statistical software package was used for
all analyses. For real-time PCR data, the statistical analy-
sis of hsa-miR-125a-3p/5p expression levels in NSCLC
tissues and corresponding LAC tissues was log2 trans-
formed. Paired-samples T-test was used to analyze signif-
icant differences in hsa-miR-125a-3p/5p expression
between NSCLC and LAC tissues. All values are
expressed as mean ± SD. The Chi-square test was used to
determine the relationship between hsa-miR-125a-3p/5p
expression and clinicopathological variables. The two-
sided Fisher's exact test to determine the relationship
between hsa-miR-125a-3p/5p expression and clinico-
pathological variables when the number of tumors ana-
lyzed was less than 5 [21]. The Mann-Whitney test was
used for pathological grade and clinical stage ranked data
analysis. Spearman correlation analysis was used to
determine the correlation between hsa-miR-125a-3p/5p
expression and clinical stage and lymph node metastasis
status. Other results were analyzed using independent
samples T-test. Results were considered to be statistically
significant at values of p < 0.05.
Results
Downregulation of hsa-miR-125a-3p/-5p expression in 
NSCLC tissues
Although it has been observed that expression of hsa-
miR-125a-5p is downregulated in NSCLC using miRNA
microarray analysis, expression levels of hsa-miR-125a-
3p in NSCLC remain unknown. Therefore, we examined
the relative expression of hsa-miR-125a-3p and hsa-miR-
125a-5p in 52 NSCLCs and paired LACs by real-time
PCR. Expression of RNU6B was used as an internal stan-
dard. Expression of hsa-miR-125a-3p/5p decreased in
NSCLCs in comparison to matched LACs (p < 0.05,
AUC-3p = 0.735, AUC-5p = 0.845, Fig 1 and Fig 2, Addi-
tional file 1). The mean expression levels of hsa-miR-
125a-3p in NSCLCs was decreased approximate 4.5 folds
of that in LACs (p < 0.001, Fig 3A) and hsa-miR-125a-5p
was decreased approximate 6 folds (p < 0.001, Fig 3B).
Correlation between hsa-miR-125a-3p/5p expression and 
clinicopathological variables of NSCLC
To determine the effects of hsa-miR-125a-3p/5p expres-
sion on tumor initiation and progression, lung cancer
patients were divided into two groups based on the mean
level of hsa-miR-125a-3p and hsa-miR-125a-5p expres-
sion in 52 NSCLCs. The two groups were defined as fol-
lows: hsa-miR-125a-3p low expression and high
expression (1.2352 of the log2 value) and hsa-miR-125a-
5p low expression and high expression (1.8594 of the log2
value) [22]. The relationships between hsa-miR-125a-3p/
5p expression and clinicopathological variables for lung
cancer are shown in Table 1 and Table 2. Statistically sig-
nificant associations between hsa-miR-125a-3p and hsa-
miR-125a-5p expression and pathological stage were
observed (p = 0.012 and p = 0.002, respectively, Mann-
Whitney Test). Changes in expression of hsa-miR-125a-
3p and hsa-miR-125a-5p were also statistically signifi-
cantly associated with lymph node metastasis in lung
cancer (p = 0.034 and p = 0.042, respectively, Two-sided
Fisher's Exact Test). No correlation was observed
between hsa-miR-125a-3p/5p expression and gender, his-
tology type, or pathological grade. However, the hsa-miR-
125a-3p expression level was correlated with age (p =
Jiang et al. BMC Cancer 2010, 10:318
http://www.biomedcentral.com/1471-2407/10/318
Page 4 of 130.031, Chi-square Test), in contrast to that of hsa-miR-
125a-5p.
In order to better characterize the relationship between
hsa-miR-125a-3p/5p expression and pathological stage
and lymph node metastasis, we further analyzed the
pathological stage and lymph node metastasis data using
the Spearman correlation test. The results showed a neg-
ative correlation between hsa-miR-125a-3p expression
and pathological stage (r = -0.352, p = 0.011), as well as
lymph node metastasis (r = -0.326, p = 0.018). However,
the correlations between hsa-miR-125a-5p expression
and pathological stage (r = 0.439, p = 0.001) and lymph
node metastasis (r = 0.300, p = 0.031) were positive.
Predicted and confirmed mRNA targets
Results from tissue expression analysis indicated that hsa-
miR-125a-3p and hsa-miR-125a-5p are associated with
metastasis. Thus, we used computational analysis to pre-
dict metastasis-related target mRNAs of hsa-miR-125a-
3p and hsa-miR-125a-5p. The analysis was conducted
using microrna.org and the TargetScanHuman 5.1 and
MiRBase webservers. Target predictions from
Figure 1 Relative expression of hsa-miR-125a-3p in lung cancer tissues. The relative expression of hsa-miR-125a-3p decreased in 52 NSCLCs in 
comparison to corresponding LACs. The data are representative of three independent experiments, and the relative expression values were calculated 
using the equation RQ = 2-ΔΔCt.
Figure 2 Relative expression of hsa-miR-125a-5p in lung cancer tissues. The relative expression of hsa-miR-125a-5p decreased in 52 NSCLCs in 
comparison to corresponding LACs. The results are representative of three independent experiments, and the relative expression values were calcu-
lated using the equation RQ = 2-ΔΔCt.
Jiang et al. BMC Cancer 2010, 10:318
http://www.biomedcentral.com/1471-2407/10/318
Page 5 of 13Microrna.org and MiRBase are based on the miRanda
algorithm. TargetScanHuman5.1 utilized the TargetScan
algorithm. The relationships between hsa-miR-125a-3p/
5p and their potential target genes identified from these
three databases are shown in Fig.4, Additional file 2, and
Additional file 3. The details of these target genes are
shown in Additional file 4 and Additional file 5.
Downregulation of hsa-miR-125a-3p/5p expression in 
NSCLC cell lines
In order to identify suitable cell lines for further studies,
we examined the relative expression levels of hsa-miR-
125a-3p/5p in four lung cancer cell lines (LH7, A549,
SPC-A-1, and NCI-H460). Expression of hsa-miR-125a-
3p/5p in the lung cancer cell lines was normalized to that
of a control human bronchiolar epithelium (HBE) cell
line. U18 was used as an internal standard for real-time
PCR. We found that the expression levels of hsa-miR-
125a-3p and hsa-miR-125a-5p were lower in each of the
four lung cancer cell lines than in the HBE cell line. The
mean level of hsa-miR-125a-3p expression was moder-
ately decreased in A549 cells (p < 0.001, Fig 5A), and the
mean level of hsa-miR-125a-5p expression was moder-
ately decreased in SPC-A-1 cells (p < 0.001, Fig 5B).
Therefore, we chose the A549 cell line for further studies
regarding hsa-miR-125a-3p and the SPC-A-1 cell line for
further studies regarding hsa-miR-125a-5p.
Effects of gain-of-function of hsa-miR-125a-3p/5p on 
migratory and invasive capabilities of A549 and SPC-A-1 
cells
To determine whether hsa-miR-125a-3p and hsa-miR-
125a-5p are associated with migration and invasion in
lung cancer cells, we adopted a gain-of-function
approach. The quantities of hsa-miR-125a-3p/5p were
exogenously increased by transfection of sense 2'-O-
methyl oligonucleotides into A549/SPC-A-1 cells. We
first utilized real-time PCR to analyze the expression of
hsa-miR-125a-3p/5p to ensure that transfection with
sense 2'-O-methyl oligonucleotides increased its expres-
sion after 24 hours. Expression in transfected cells was
normalized to that of untreated cells, and U18 expression
was used as an internal standard. The results showed
that, in comparison to the control untreated groups, the
mean levels of expression of both hsa-miR-125a-3p and
hsa-miR-125a-5p in the sense groups were significantly
increased (p < 0.001 for both, Fig 6A and 6B).
We next analyzed the migratory capabilities of cells
overexpressing hsa-miR-125a-3p/5p using transwell
chambers. For analysis of hsa-miR-125a-3p, the number
of A549 cells in the untreated group that migrated
through a microporous membrane was 31.20 ± 1.64.
There was no difference between untreated cells and cells
transfected with the scramble-3p oligonucleotide (31.40
± 0.55, p = 0.807). However, the number of migrating cells
Figure 3 Mean levels of hsa-miR-125a-3p and hsa-miR-125a-5p in lung cancer tissues. (A) The mean level of hsa-miR-125a-3p relative expres-
sion in 52 NSCLCs. (B) The mean level of hsa-miR-125a-5p relative expression in 52 NSCLCs. The values represent the means of three replicates, and 
the relative expression values were calculated using the equation RQ = 2-ΔΔCt.
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with the sense-3p oligonucleotide (16.40 ± 2.07, p <
0.001). For hsa-miR-125a-5p, the number of SPC-A-1
cells in the untreated group that migrated through the
microporous membrane was 26.60 ± 2.07. Again no dif-
ference was observed between untreated cells and cells
transfected with the scramble-5p oligonucleotide (25.60
± 1.67, p = 0.426). However, the number of migrating cells
increased significantly when cells were transfected with
the sense-5p oligonucleotide (38.80 ± 1.92, p < 0.001, Fig
7).
In the hsa-miR-125a-3p invasion analysis, the number
of A549 cells in the untreated group that invaded through
the Matrigel was 24.40 ±2.41. There was no difference
between untreated cells and cells transfected with the
scramble-3p oligonucleotide (24.80 ± 3.03, p = 0.823).
The number of invading cells decreased significantly
when cells were transfected with the sense-3p oligonucle-
otide (12.20 ± 1.58, p < 0.001). In the invasion assay for
hsa-miR-125a-5p, the number of SPC-A-1 cells in the
untreated group that invaded through the Matrigel was
22.20 ± 1.72. Again no significant difference was
observed between untreated cells and cells transfected
with the scramble-5p oligonucleotide (23.40 ± 2.34, p =
1.000). However, the number of invading cells increased
significantly when cells were transfected with the sense-
5p oligonucleotide (30.80 ± 1.92, p < 0.001, Fig 7).
Effects loss-of-function of hsa-miR-125a-3p/5p on the 
migratory and invasive capabilities of A549 and SPC-A-1 
cells
To further examine whether endogenous hsa-miR-125a-
3p and hsa-miR-125a-5p regulate migration and invasion,
we adopted a loss-of-function approach that blocked the
function of endogenous hsa-miR-125a-3p and hsa-miR-
125a-5p using antisense 2'-O-methyl oligonucleotides
[23-26]. We then analyzed the migratory and invasive
capabilities of these cells using the methods described
above. In the hsa-miR-125a-3p migration assay, the num-
ber of A549 cells in the untreated group that migrated
Table 1: Relationship between hsa-miR-125a-3p expression and clinical pathological factors in lung cancinoma
hsa-miR-125a-3p
Variable Patients Low expression(%) High expression(%) p value
Gender
Male 33 12 (36.4) 21 (63.6)
Female 19 6 (31.6) 13 (68.4) 0.727b
Age
≤ 60 28 22 (78.6) 6 (21.4)
> 60 24 12 (50.0) 12 (50.0) 0.031b
Histology type
Squamous cancer 22 13 (59.1) 9 (40.9)
Adenocarcinoma 30 21 (70.0) 9 (30.0) 0.414b
Pathological grade
I 8 7 (87.5) 1 (12.5)
II 28 17 (60.7) 11 (39.3)
III 16 10 (62.5) 6 (37.5) 0.370c
Pathological stage
I 18 8 (44.4) 10 (55.6)
II 15 10 (66.7) 5 (33.3)
III 19 16 (80.0) 3 (20.0) 0.012c
Lymph node status
No metastasis 32 17 (53.1) 15 (46.9)
Metastasis 20 17 (85.0) 3 (15.0) 0.034a
a Two-sided Fisher's Exact Test.
b Chi-square Test
c Mann-whitney Test
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There was no difference between the untreated and
scramble-3p-transfected cells (32.00 ± 0.58, p = 0.347).
The number of migrating cells was significantly increased
when A549 cells were transfected with the antisense-3p
oligonucleotide (46.00 ± 3.16, p < 0.001). For the hsa-
miR-125a-5p migration assay, the number of SPC-A-1
cells in the untreated group that migrated through the
microporous membrane was 22.60 ± 2.07. No difference
was observed between untreated and scramble-5p-trans-
fected cells (22.40 ± 1.14, p = 0.855). The number of
migrating cells was significantly decreased when SPC-A-
1 cells were transfected with the antisense-5p oligonucle-
otide (15.00 ± 1.58, p < 0.001, Fig 8).
In the hsa-miR-125a-3p invasion assay, the number of
A549 cells in the untreated group that invaded through
the Matrigel was 25.00 ± 1.51. There was no difference
between untreated and scramble-3p-transfected cells
(24.60 ± 3.04, p = 0.801). The number of invading cells
was significantly increased when A549 cells were trans-
fected with the antisense-3p oligonucleotide (37.00 ±
2.73, p < 0.001). In the hsa-miR-125a-5p invasion assay,
the number of SPC-A-1 cells in the untreated group that
invaded through the Matrigel was 21.00 ± 1.59. No signif-
icant difference was observed between untreated and
scramble-5p-transfected cells (20.80 ± 0.84, p = 0.809).
The number of invading SPC-A-1 cells decreased signifi-
cantly when cells were transfected with the antisense-5p
oligonucleotide (11.00 ± 1.07, p < 0.001, Fig 8).
Discussion
MiRNAs have emerged as important regulators of tum-
origenesis [27,28]. Mounting evidence has shown that
miRNAs are frequently mutated or differentially
expressed in human cancers, suggesting that miRNAs
may act as tumor suppressors or oncogenes depending on
whether their specific targets act as oncogenes or tumor
suppressors [29]. Therefore, tumor suppressor miRNAs
are generally expressed at low levels [30,31] and onco-
genic miRNAs are expressed at high levels in tumors or
Table 2: Relationship between hsa-miR-125a-5p expression and clinical pathological factors in lung cancinoma
hsa-miR-125a-5p
Variable Patients Low expression(%) High expression(%) p value
Gender
Male 33 14 (42.4) 19 (57.6)
Female 19 6 (31.6) 13 (68.4) 0.439b
Age
≤ 60 28 11 (39.3) 17 (60.7)
> 60 24 9 (37.5) 15 (62.5) 1.000b
Histology type
Squamous cancer 22 9 (40.9) 13 (59.1)
Adenocarcinoma 30 11 (36.7) 19 (63.3) 0.780b
Pathological grade
I 8 4 (50.0) 4 (50.0)
II 28 11 (39.3) 17 (60.7)
III 16 5 (31.3) 11 (68.7) 0.380c
Pathological stage
I 18 12 (66.7) 6 (33.3)
II 15 5 (33.3) 10 (66.7)
III 19 3 (15.8) 16 (84.2) 0.002c
Lymph node status
No metastasis 32 16 (50.0) 16 (50.0)
Metastasis 20 4 (20.0) 16 (80.0) 0.042a
a Two-sided Fisher's Exact Test.
b Chi-square Test
c Mann-whitney Test
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Figure 4 Prediction of hsa-miR-125a-3p and hsa-miR-125a-5p target genes. Predictions were conducted using microrna.Org, TargetScanHuman 
5.1, and MiRBase webservers. Microrna.org and MiRBase predictions are based on the miRanda algorithm, while TargetScanHuman5.1 predictions are 
based on the TargetScan algorithm.
Figure 5 Relative expression of hsa-miR-125a-3p and hsa-miR-125a-5p in different lung cancer cell lines. (A) The relative expression levels of 
hsa-miR-125a-3p in four lung cancer cell lines, particularly the NCI-H460 cell line, were all lower than that of the HBE cell line. (B) The relative expression 
levels of hsa-miR-125a-5p in four lung cancer cell lines, particularly the A459 cell line, were all lower than that of the HBE cell line. The results are rep-
resentative of three independent experiments, and the relative expression values were calculated using the equation RQ = 2-ΔΔCt.
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specific characterization of miRNA expression and func-
tion could lead to the identification of novel biomarkers
to predict clinical outcomes in the future [34-37].
In the present study, we report that expression of hsa-
miR-125a-3p and hsa-miR-125a-5p is dysregulated in
lung cancer. Consistent with the results of Yanainhara
[20], real-time PCR results showed that expression of
hsa-miR-125a-5p was decreased significantly in the
majority of NSCLCs in comparison to matched LACs. In
addition, we also found that expression of hsa-miR-125a-
3p was significantly reduced. This expression pattern
suggests that hsa-miR-125a-3p and hsa-miR-125a-5p
may act as tumor suppressors by regulating expression of
a subset of oncogenes. These specific alterations in
expression may be characteristic of human lung cancer
and may contribute to lung tumorigenesis.
Tumor invasion and metastasis are the most common
cause of cancer deaths worldwide [38,39]. Studies regard-
ing the functions of miRNAs in tumor invasion and
metastasis currently represent a major focus in cancer
biology [14,40]. In this study, we evaluated the correlation
between hsa-miR-125a-3p/5p expression levels and clini-
copathological variables in 52 NSCLC tissues. Interest-
ingly, we found that hsa-miR-125a-3p/5p expression
levels were correlated with pathological stage and lymph
node metastasis. Together with our functional studies in
lung cancer cells, these results suggest that hsa-miR-
125a-3p and hsa-miR-125a-5p function in opposite man-
ners to suppress and enhance cell migration and invasion
of lung cancer cells, respectively, which may in turn affect
lymph node metastasis in NSCLC.
The specific mechanisms that lead to changes in cell
migration and invasion regulated by hsa-miR-125a-3p/5p
in lung cancer cells remain unknown. MiRNAs are com-
monly thought to posttranscriptionally regulate mRNA
degradation and inhibition of mRNA translation via
interactions with the 3'-untranslated regions (UTRs) of
target mRNAs in animals [16-18]. However, there are sev-
eral remaining gaps in our knowledge of miRNA function
that have been revealed by recent studies. Recently, a few
experiments have indicated possible target sites in the 5'-
UTR of mRNAs [41]. Furthermore, 0rom and colleagues
[7] found that miRNA-10a binds the 5'UTR of ribosomal
protein mRNAs and enhances their translation. There-
fore, the regulatory mechanisms controlled by miRNAs
are may be more varied and extensive than previously
thought.
According to predicted results from three webserver
databases, CCL4 and IGF-2 were the most likely target
Figure 6 Relative levels of hsa-miR-125a-3p and hsa-miR-125a-5p were increased by transfection with sense 2'-O-methyl oligonucleotides. 
(A) The relative levels of hsa-miR-125a-3p were significantly increased in the sense-3p-transfected group. (B) The relative levels of hsa-miR-125a-5p 
were significantly increased in the sense-5p-transfected group. The results are representative of three independent experiments, and the relative ex-
pression values were calculated using the equation RQ = 2-ΔΔCt.
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Figure 7 Effects of gain-of-function of hsa-miR-125a-3p/5p on migration and invasion of lung cancer cells. Migration assay results showed 
that the number of A549 cells that migrated through the microporous membrane was significantly decreased in the sense-3p group (p < 0.001). In 
contrast, the number of migratory SPC-A-1 cells was significantly increased in the sense-5p group (p < 0.001, bar = 20 μm). Invasion assay results 
showed that the number of A549 cells that invaded through the Matrigel was significantly decreased in the sense-3p group (p < 0.001). However, the 
number of invasive SPC-A-1 cells significantly increased in the sense-5p group (p < 0.001, bar = 20 μm). The results are representative of three inde-
pendent experiments.
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Figure 8 Effects of loss-of-function of hsa-miR-125a-3p/5p on migration and invasion of lung cancer cells. Migration assay results showed that 
the number of A549 cells that migrated through the microporous membrane was significantly increased in the antisense-3p group (p < 0.001). How-
ever, the number of migratory SPC-A-1 cells was significantly decreased in the antisense-5p group (p < 0.001, bar = 20 μm). Invasion assay results 
showed that the number of A549 cells that invaded through the Matrigel was significantly increased in the antisense-3p group (p < 0.001). In contrast, 
the number of invasive SPC-A-1 cells was significantly decreased in the antisense-5p group (p < 0.001, bar = 20 μm). The results are representative of 
three independent experiments.
Jiang et al. BMC Cancer 2010, 10:318
http://www.biomedcentral.com/1471-2407/10/318
Page 12 of 13genes of hsa-miR-125a-3p, while IL16 and CCL21 were
the most likely target genes of hsa-miR-125a-5p. CCL4
(MIP-1beta), a member of the CC chemokine family,
induces cellular migration and invasion through interac-
tions with its receptor CCR5 [42,43]. Nussbaum and col-
leagues [44] have reported that IGF-2 and its receptor
IGF-2R stimulate tumor cell migration in human hepato-
carcinogenesis. IL-16, an activator of the plasminogen-
plasmin system, promotes human eosinophil migration
into the extracellular matrix via a CCR3-chemokine-
mediated signaling pathway [45]. Previous results from
our laboratory indicated that CCR7 and its ligand CCL21
regulate migration and invasion of lung cancer cells
through the ERK1/2 pathway under hypoxic conditions
and promote metastasis of lung cancer [46]. Therefore,
the complicated regulatory mechanisms controlled by
hsa-miR-125a-3p and hsa-miR-125a-5p may play com-
plex roles in migration and invasion. Despite the neces-
sity for further studies to understand these mechanisms,
our findings suggest a crucial role for miR-125a in lung
cancer.
Conclusion
The results from this study demonstrate that hsa-miR-
125a-3p and hsa-miR-125a-5p, two miRNAs that are
downregulated in NSCLC, are associated with lymph
node metastasis. In vitro functional studies in lung cancer
cells revealed that hsa-miR-125a-3p and hsa-miR-125a-
5p appear to play opposite cellular roles, suppressing and
enhancing cell migration and invasion, respectively.
Thus, these results may lead to the identification of novel




The authors declare that they have no competing interests.
Authors' contributions
LJ initiated the research, carried out the experiments, and wrote the manu-
script. QH and SZ contributed to translation of the paper. QZ and JC provided
experimental instruction. XQ helped with the experimental design and pro-
vided funding support. EW provided critical review of the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
We are very grateful to Dr. Baoshen Zhou from the Department of Epidemiol-
ogy, School of Public Health, China Medical University for statistical analysis. We 
are also grateful to the members of our laboratory for useful suggestions.
Author Details
1Department of Pathology, the First Affiliated Hospital of China Medical 
University, No. 92 North Second Road, Heping District, Shenyang, Liaoning 
110001, China, 2Department of Pathology, College of Basic Medical Sciences, 
China Medical University, No. 92 North Second Road, Heping District, 
Shenyang, Liaoning 110001, China and 3Center of Laboratory Technology and 
Experimental Medicine, China Medical University, No. 92 North Second Road, 
Heping District, Shenyang, Liaoning 110001, China
References
1. Lee RC, Feinbaum RL, Ambros V: The C. elegans heterochronic gene lin-4 
encodes small RNAs with antisense complementarity to lin-14.  Cell 
1993, 75:843-54.
2. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Rådmark O, Kim S, 
Kim VN: The nuclear RNase III Drosha initiates microRNA processing.  
Nature 2003, 425:415-9.
3. Kong W, Zhao JJ, He L, Cheng JQ: Strategies for profiling microRNA 
expression.  J Cell Physiol 2009, 218:22-5.
4. Hutvágner G, McLachlan J, Pasquinelli AE, Bálint E, Tuschl T, Zamore PD: A 
cellular function for the RNA-interference enzyme Dicer in the 
maturation of the let-7 small temporal RNA.  Science 2001, 293:834-8.
5. Grishok A, Pasquinelli AE, Conte D, Li N, Parrish S, Ha I, Baillie DL, Fire A, 
Ruvkun G, Mello CC: Genes and mechanisms related to RNA 
interference regulate expression of the small temporal RNAs that 
control C. elegans developmental timing.  Cell 2001, 106:23-34.
6. Schwarz DS, Hutvágner G, Du T, Xu Z, Aronin N, Zamore PD: Asymmetry 
in the assembly of the RNAi enzyme complex.  Cell 2003, 115:199-208.
7. Ørom UA, Nielsen FC, Lund AH: MicroRNA-10a binds the 5'UTR of 
ribosomal protein mRNAs and enhances their translation.  Mol Cell 
2008, 30:460-71.
8. Brennecke J, Stark A, Russell RB, Cohen SM: Principles of microRNA-target 
recognition.  PLoS Biol 2005, 3:e85.
9. Bartel DP: MicroRNAs genomics, biogenesis, mechanism, and function.  
Cell 2004, 116:281-297.
10. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, 
Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM: Human microRNA 
genes are frequently located at fragile sites and genomic regions 
involved in cancers.  Proc Natl Acad Sci USA 2004, 101:2999-3004.
11. Crawford M, Brawner E, Batte K, Yu L, Hunter MG, Otterson GA, Nuovo G, 
Marsh CB, Nana-Sinkam SP: MicroRNA-126 inhibits invasion in non-
small cell lung carcinoma cell lines.  Biochem Biophys Res Commun 2008, 
373:607-12.
12. Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY: MicroRNA-21 targets tumor 
suppressor genes in invasion and metastasis.  Cell Res 2008, 18:350-9.
13. Tavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, 
Massagué J: Endogenous human microRNAs that suppress breast 
cancer metastasis.  Nature 2008, 451:147-52.
14. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA: MicroRNAs -- the 
micro steering wheel of tumour metastases.  Nat Rev Cancer 2009, 
9:293-302.
15. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szász AM, Wang ZC, Brock 
JE, Richardson AL, Weinberg RA: A pleiotropically acting microRNA miR-
31, inhibits breast cancer metastasis.  Cell 2009, 137:1032-46.
16. Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, Cheng JQ: 
MicroRNA-155 is regulated by the transforming growth factor beta/
Smad pathway and contributes to epithelial cell plasticity by targeting 
RhoA.  Mol Cell Biol 2008, 28:6773-84.
17. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, 
Allgayer H: MicroRNA-21 (miR-21) posttranscriptionally downregulates 
Additional file 1 The specificity and sensitivity of hsa-miR-125a-3p 
and hsa-miR-125a-5p. (A) The specificity and sensitivity of hsa-miR-125a-
3p was analyzed by DOC Curve. (B) The specificity and sensitivity of hsa-
miR-125a-5p was analyzed by DOC Curve.
Additional file 2 Prediction of target sites for hsa-miR-125a-3p and 
target mRNAs in three databases. The target sites for hsa-miR-125a-3p 
and the target mRNAs were predicted using microrna.org, TargetScanHu-
man 5.1 and MiRBase webservers to further illustrate results shown in Fig. 4.
Additional file 3 Prediction of target sites for hsa-miR-125a-5p and 
target mRNAs in three databases. The target sites of hsa-miR-125a-5p 
and the target mRNAs were predicted using microrna.org, TargetScanHu-
man 5.1 and MiRBase webservers to further illustrate results shown in Fig. 4.
Additional file 4 Details of the target genes of hsa-miR-125a-3p. 
Details of the target genes of hsa-miR-125a-3p.
Additional file 5 Details of the target genes of hsa-miR-125a-5p. 
Details of the target genes of hsa-miR-125a-5p.
Received: 24 November 2009 Accepted: 22 June 2010 
Published: 22 June 2010
This article is available from: http://www.biomedcentral.com/1471-2407/10/318© 2010 Jiang et l; lic nsee BioMed Central Ltd. is an Open Access article distributed under th  terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC C c r 2010, 10:318
Jiang et al. BMC Cancer 2010, 10:318
http://www.biomedcentral.com/1471-2407/10/318
Page 13 of 13tumor suppressor Pdcd4 and stimulates invasion, intravasation and 
metastasis in colorectal cancer.  Oncogene 2008, 27:2128-2136.
18. Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, 
Krichevsky AM: MicroRNA 21 promotes glioma invasion by targeting 
matrix metalloproteinase regulators.  Mol Cell Biol 2008, 28:5369-5380.
19. Yang J, Mani SA, Weinberg RA: Exploring a new twist on tumor 
metastasis.  Cancer Res 2006, 66:4549-4552.
20. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens 
RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC: 
Unique microRNA molecular profiles in lung cancer diagnosis and 
prognosis.  Cancer Cell 2006, 9:189-98.
21. Agresti Alan: A Survey of Exact Inference for Contingency Tables.  
Statistical Science 1992, 7:131-177.
22. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY: 
MicroRNA miR-21 overexpression in human breast cancer is associated 
with advanced clinical stage, lymph node metastasis and patient poor 
prognosis.  RNA 2008, 14:2348-60.
23. Séguin RM, Ferrari N: Emerging oligonucleotide therapies for asthma 
and chronic obstructive pulmonary disease.  Expert Opin InvestigDrugs 
2009, 18:1505-17.
24. Cheng AM, Byrom MW, Shelton J, Ford LP: Antisense inhibition of human 
miRNAs and indications for an involvement of miRNA in cell growth 
and apoptosis.  Nucleic Acids Res 2005, 33:1290-1297.
25. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT: c-Myc-
regulated microRNAs modulate E2F1 expression.  Nature 2005, 
435:839-843.
26. Fabani MM, Gait MJ: miR-122 targeting with LNA/2¢-O-methyl 
oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA -
peptide conjugates.  RNA 2008, 14:336-346.
27. Chen HC, Chen GH, Chen YH, Liao WL, Liu CY, Chang KP, Chang YS, Chen 
SJ: MicroRNA deregulation and pathway alterations in nasopharyngeal 
carcinoma.  Br J Cancer 2009, 100:1002-11.
28. Deng S, Calin GA, Croce CM, Coukos G, Zhang L: Mechanisms of 
microRNA deregulation in human cancer.  Cell Cycle 2008, 7:2643-6.
29. Zhang B, Pan X, Cobb GP, Anderson TA: microRNAs as oncogenes and 
tumor suppressors.  Dev Biol 2007, 302:1-12.
30. Inamura K, Togashi Y, Nomura K, Ninomiya H, Hiramatsu M, Satoh Y, 
Okumura S, Nakagawa K, Ishikawa Y: let-7 microRNA expression is 
reduced in bronchioloalveolar carcinoma, a non-invasive carcinoma, 
and is not correlated with prognosis.  Lung Cancer 2007, 58:392-6.
31. Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M, Taccioli 
C, Zanesi N, Garzon R, Aqeilan RI, Alder H, Volinia S, Rassenti L, Liu X, Liu 
CG, Kipps TJ, Negrini M, Croce CM: MiR-15a and miR-16-1 cluster 
functions in human leukemia.  Proc Natl Acad Sci USA 2008, 105:5166-71.
32. Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, Lianidou 
ES: Prognostic value of mature microRNA-21 and microRNA-205 
overexpression in non-small cell lung cancer by quantitative real-time 
RT-PCR.  Clin Chem 2008, 4:1696-704.
33. Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, Lund E, Dahlberg JE: 
Accumulation of miR-155 and BIC RNA in human B cell lymphomas.  
Proc Natl Acad Sci USA 2005, 102:3627-32.
34. Habbe N, Koorstra JB, Mendell JT, Offerhaus GJ, Ryu JK, Feldmann G, 
Mullendore ME, Goggins MG, Hong SM, Maitra A: MicroRNA miR-155 is a 
biomarker of early pancreatic neoplasia.  Cancer Biol Ther 2009, 8:340-6.
35. Caldas C, Brenton JD: Sizing up miRNAs as cancer genes.  Nat Med 2005, 
11:712-714.
36. Iorio MV, Casalini P, Tagliabue E, Ménard S, Croce CM: MicroRNA profiling 
as a tool to understand prognosis, therapy response and resistance in 
breast cancer.  Eur J Cancer 2008, 44:2753-9.
37. Tavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, 
Massagué J: Endogenous human microRNAs that suppress breast 
cancer metastasis.  Nature 2008, 451:147-52.
38. Geiger TR, Peeper DS: Metastasis mechanisms.  Biochim BiophysActa 
2009, 1796:293-308.
39. Hedley BD, Chambers AF: Tumor dormancy and metastasis.  Adv Cancer 
Res 2009, 102:67-101.
40. Ma L, Weinberg RA: Micromanagers of malignancy: role of microRNAs in 
regulating metastasis.  Trends Genet 2008, 24:448-56.
41. Lee I, Ajay SS, Yook JI, Kim HS, Hong SH, Kim NH, Dhanasekaran SM, 
Chinnaiyan AM, Athey BD: New class of microRNA targets containing 
simultaneous 5'-UTR and 3'-UTR interaction sites.  Genome Res 2009, 
19:1175-83.
42. Menten P, Saccani A, Dillen C, Wuyts A, Struyf S, Proost P, Mantovani A, 
Wang JM, Van Damme J: Role of the autocrine chemokines MIP-1alpha 
and MIP-1beta in the metastatic behavior of murine T cell lymphoma.  
J Leukoc Biol 2002, 72:780-9.
43. Van Deventer HW, Wu QP, Bergstralh DT, Davis BK, O'Connor BP, Ting JP, 
Serody JS: C-C chemokine receptor 5 on pulmonary fibrocytes 
facilitates migration and promotes metastasis via matrix 
metalloproteinase 9.  Am J Pathol 2008, 173:253-64.
44. Nussbaum T, Samarin J, Ehemann V, Bissinger M, Ryschich E, Khamidjanov 
A, Yu X, Gretz N, Schirmacher P, Breuhahn K: Autocrine insulin-like 
growth factor-II stimulation of tumor cell migration is a progression 
step in human hepatocarcinogenesis.  Hepatology 2008, 48:146-56.
45. Ferland C, Flamand N, Davoine F, Chakir J, Laviolette M: IL-16 Activates 
Plasminogen-Plasmin System and Promotes Human Eosinophil 
Migration into Extracellular Matrix via CCR3-Chemokine-Mediated 
Signaling and by Modulating CD4 Eosinophil Expression.  J Immunol 
2004, 173:4417-24.
46. Li Y, Qiu X, Zhang S, Zhang Q, Wang E: Hypoxia induced CCR7 expression 
via HIF-1alpha and HIF-2alpha correlates with migration and invasion 
in lung cancer cells.  Cancer Biol Ther 2009, 8:322-30.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/318/prepub
doi: 10.1186/1471-2407-10-318
Cite this article as: Jiang et al., Hsa-miR-125a-3p and hsa-miR-125a-5p are 
downregulated in non-small cell lung cancer and have inverse effects on 
invasion and migration of lung cancer cells BMC Cancer 2010, 10:318
